The rise and fall of raloxifene use for osteoporosis, 1999–2022
Authors' conclusion
Raloxifene initiation has declined substantially since 2003, and overall utilization has declined rapidly since 2012.
Study context
- Population
- Community-dwelling females aged ≥ 66 years initiating raloxifene between 1999/05 and 2022/12 through the Ontario Drug Benefit programmean age 74.2 years
- Participants
- 21,896 females
- Outcome
- Use of raloxifene over time: number of incident and prevalent users by calendar year, and persistence with therapy (60-day permissible gap)
Methodological detailspopulation-based, drug utilisation study
- Population-based
- Drug utilisation study
Main finding
As reported in the abstract
Raloxifene use over time
- Annual high of initiators, 2001
- 3,824
- Initiators in 2002 (15% drop)
- 3,252
- Initiators in 2003
- 2,113
- Initiators in 2022
- 90
- Prevalent users annually, 2003–2011
- >5,000
- Prevalent users in 2012
- 4,670
- Prevalent users in 2022
- 959
- Persisted with therapy for ≥ 3 years
- 29%
Observational data: associations, not effects.
Further findings
- Besides known population-level treatment trends (increased statins, decreased estrogen therapy), little differences in patient characteristics over time
Original publication
The rise and fall of raloxifene use for osteoporosis, 1999–2022. Osteoporos Int. Published 11 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →